Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria

This study has been withdrawn prior to enrollment.
(Drug unavailable)
Information provided by:
University of Kansas Identifier:
First received: June 20, 2007
Last updated: November 5, 2008
Last verified: November 2008

To determine whether pyridoxamine can decrease oxalate excretion in subjects who have normal oxalate excretion (but who have had kidney stones), and in subjects who have primary hyperoxaluria.

Condition Intervention Phase
Kidney Stones
Drug: Pyridoxamine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria

Further study details as provided by University of Kansas:

Primary Outcome Measures:
  • Urinary Excretion of Oxalate at Highest Dose [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Urinary Supersaturation [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: January 2007
Arms Assigned Interventions
Experimental: 1 Drug: Pyridoxamine
Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults > 18 years
  • History of stone formation
  • Good Renal function
  • Normal urinary excretion of stone-promoting chemicals(Ca, uric acid, oxalate, citrate), except for subjects with hyperoxaluria for Study

Exclusion Criteria:

  • Pregnancy
  • Hyperparathyroidism
  • Enteric hyperoxaluria.
  • Obstructive uropathy
  • Infection (struvite) stones
  • Severe dietary Ca++ restriction or deficiency
  • Recent significant cardio-vascular events
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00490113

Sponsors and Collaborators
University of Kansas
Principal Investigator: Jon I Scheinman, M.D. University of Kansas
  More Information

No publications provided

Responsible Party: Jon I Scheinman, M.D., University of Kansas Medical Center Identifier: NCT00490113     History of Changes
Other Study ID Numbers: 10417, 1 R21 DK072454-02
Study First Received: June 20, 2007
Last Updated: November 5, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Vitamin B Complex
Vitamins processed this record on March 03, 2015